Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine for prevention of postoperative nausea and vomiting after thoracoscopic lung cancer surgery
ChiCTR2400083262Phase 4Not yet recruiting
- Sponsor
- Henan Provincial Chest Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of penehyclidine in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Henan Provincial Chest Hospital. Primary endpoint: Total incidence of postoperative nausea and vomiting (PONV). Planned start Apr 2024; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2400083262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083262.